CivaSheet for Pancreatic Cancer
Official title: Commercializing CivaSheet for Pancreatic Cancer Patients
Funded at Civatech Oncology, INC. · NIH-11117056 · Data updated 2026-11-12
This work focuses on making a special radiation sheet called CivaSheet available to help people with pancreatic cancer by delivering radiation directly to the tumor.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Civatech Oncology, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | September 13, 2016 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,017,318 |
| NIH project number | 5R44CA210770-06 |
| Project ID | NIH-11117056 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with pancreatic cancer who are undergoing surgery and could benefit from targeted radiation therapy.
✕Less likely to help
Patients who are not candidates for surgery or whose cancer has spread widely may not directly benefit from this specific treatment.
What this research studies
CivaSheet is a unique, flexible radiation source that can be placed during surgery for pancreatic cancer. It delivers radiation precisely to the diseased area while protecting nearby healthy tissues. This innovative approach aims to reduce the chance of cancer returning locally and shorten the time between surgery and radiation treatment. Patients in early clinical experiences have shown good recovery without negative effects from the device.
Why it matters
Potential benefit: If successful, this technology could significantly improve outcomes for pancreatic cancer patients by preventing local recurrence and minimizing side effects from radiation.
How similar studies have gone: This novel, polymer-encapsulated radiation source has already shown success in clinical trials by eliminating local recurrence in pancreatic cancer patients and has received FDA clearance.
Where this research is happening
-
Civatech Oncology, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Perez, Kristy — Civatech Oncology, INC.
- Study coordinator: Perez, Kristy
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.